Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 24:14:1214975.
doi: 10.3389/fendo.2023.1214975. eCollection 2023.

User experiences during the transition to calibration-free sensors with remote monitoring while using automated insulin delivery - a qualitative study

Affiliations

User experiences during the transition to calibration-free sensors with remote monitoring while using automated insulin delivery - a qualitative study

Shekhar Sehgal et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: To evaluate the experiences of patients with type 1 diabetes following transition from a calibration-requiring to a calibration-free sensor and remote monitoring in the context of using automated insulin delivery (AID).

Research design and methods: Fifteen participants aged 7-65 years with type 1 diabetes participating in a longitudinal study used a Medtronic® advanced hybrid closed loop (AHCL) device with initially calibration-requiring then calibration-free sensors. Qualitative interviews were conducted ≥20 weeks following use of the calibration-requiring and ≥4 weeks after use of the calibration-free sensors/remote monitoring. Thematic analysis was used to identify key themes and subthemes.

Results: At baseline, mean diabetes duration was 14.5 years ( ± 10.9), mean Hba1c 54.8 mmol/mol ( ± 10.2) (7.2 ± 0.9%) and Time in range 75.4% ( ± 11.6). Participants reported a progressive improvement in digital and lifestyle integration, and device trust following transition to calibration-free sensors with remote monitoring potential. They also reported a reduced need for capillary glucose, increased device satisfaction and trust, and reduced burden of diabetes care. Negative aspects reported included periodic early sensor loss, and for some, impaired integration with mobile devices.

Conclusion: Transitioning to calibration-free sensors with remote monitoring while using AHCL was associated with better user experience, including perceptions of improved quality of life and a reduced burden of diabetes care. Appropriate expectation setting, training, and ongoing support allow for the optimal user experience while using AHCL.

Clinical trial registration: https://www.anzctr.org.au, identifier ACTRN12621000360819.

Keywords: continuous glucose monitoring; interview; patient satisfaction; remote monitoring; type 1 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Author BW has previously received research funding from Dexcom, Medtronic and iSENS. Author MD received Research funding from: Novo Nordisk, Medtronic, Dexcom, Pfizer and Research support from Medtronic, Dexcom, SOOIL, Honoraria from Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Leelarathna L, Choudhary P, Wilmot EG, Lumb A, Street T, Kar P, et al. Hybrid closed-loop therapy: Where are we in 2021? Diabetes Obes Metab (2021) 23(3):655–60. doi: 10.1111/dom.14273 - DOI - PubMed
    1. Pease A, Lo C, Earnest A, Kiriakova V, Liew D, Zoungas S. The efficacy of technology in type 1 diabetes: A systematic review, network meta-analysis, and narrative synthesis. Diabetes Technol Ther (2020) 22(5):411–21. doi: 10.1089/dia.2019.0417 - DOI - PubMed
    1. Collyns OJ, Meier RA, Betts ZL, Chan DS, Frampton C, Frewen CM, et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care (2021) 44(4):969–75. doi: 10.2337/dc20-2250 - DOI - PubMed
    1. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med (2019) 381(18):1707–17. doi: 10.1056/NEJMoa1907863 - DOI - PMC - PubMed
    1. Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med (2015) 373(22):2129–40. doi: 10.1056/NEJMoa1509351 - DOI - PMC - PubMed

Publication types